Suven's Ropanicant Meets Primary Endpoint in Phase 2b Trial for Major Depressive Disorder
核心洞察
Ropanicant 45 mg twice-daily met the primary endpoint with a clinically meaningful MADRS score improvement versus placebo at Week 6 (ML-estimated mean difference: -3.572, p=0.038).
Secondary endpoints including the Sheehan Disability Scale (p=0.039) also showed evidence of treatment benefit, with CGI-S and QLDS trending favorably.
Ropanicant was generally well tolerated, with most adverse events mild to moderate and no unexpected safety signals identified.
Suven Life Sciences has announced that its investigational drug Ropanicant (SUVN-911) met the primary endpoint in a Phase 2b randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating efficacy and safety in patients with major depressive disorder (搜索) (MDD). The twice-daily oral administration of Ropanicant 45 mg demonstrated a clinically meaningful improvement from baseline in the Montgomery–Åsberg Depression Rating Scale (MADRS) total score at Week 6 compared to placebo.
The maximum likelihood (ML)-estimated mean difference from baseline versus placebo was -3.572 in the Full Analysis Set (p=0.038), -3.570 in the modified Full Analysis Set (p=0.038), and -4.067 in the Per-Protocol Set (p=0.023). Baseline demographic and clinical characteristics were comparable across placebo and treatment groups, indicating a balanced study population.
Secondary and Exploratory Endpoints
Evidence of treatment benefit was also observed across several secondary endpoints. The Clinical Global Impression–Severity of Illness (CGI-S) scale showed a trend toward improvement (p=0.094), while the Sheehan Disability Scale (SDS) reached statistical significance (p=0.039). Improvements were additionally seen in the exploratory Quality of Life in Depression Scale (QLDS) (p=0.068). Mean baseline scores for depression severity, global illness severity, functional impairment, quality of life, pleasure, and depressive symptoms were reported to be similar across all study arms.
Safety and Tolerability Profile
Ropanicant was generally well tolerated among participants. Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity, with no unexpected safety signals identified during the trial. The company reported that most adverse events were transient and resolved without clinically significant intervention.
Assessment of clinical laboratory parameters showed no meaningful treatment-related changes and no patterns suggesting adverse effects on haematology, clinical chemistry, or urinalysis evaluations. No clinically relevant effects were observed on electrocardiogram (ECG) parameters. Furthermore, no clinically meaningful changes were detected in vital signs, including blood pressure, heart rate, respiratory rate, body weight, or body temperature. Physical examination findings remained generally unchanged throughout the study.
Unmet Need in Major Depressive Disorder (搜索)
MDD remains the leading cause of disability worldwide, and approximately 50% of patients do not adequately benefit from standard first-line antidepressant therapies, according to Ramakrishna Nirogi, President and Chief Scientific Officer of Suven Life Sciences. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, emphasized that "there is still a significant unmet medical need despite the availability of multiple approved therapies for MDD," adding that the company "strongly believes that Ropanicant would offer a differentiated treatment option to meet the unmet medical need."
Next Steps and Regulatory Pathway
Suven Life Sciences stated that detailed findings from the study will be presented at future medical conferences and/or published in peer-reviewed journals. The company disclosed that a priority patent application covering additional findings, therapeutic use, and treatment methods related to Ropanicant has already been filed, with an international patent application claiming priority from the filing expected to be submitted shortly.
Nirogi noted that the Phase 2b data "strongly supports the potential of Ropanicant as a promising treatment for MDD" and confirmed that the company looks forward to "engaging with regulatory authorities worldwide to discuss Phase 3 clinical development plans of Ropanicant." The study, first submitted on February 18, 2025, is now listed as completed on ClinicalTrials.gov, marking a key proof-of-concept milestone ahead of any Phase 3 decision.